QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
NYSE:MCK

McKesson (MCK) Stock Price, News & Analysis

$494.23
-22.75 (-4.40%)
(As of 02/8/2024 ET)
Today's Range
$488.29
$510.73
50-Day Range
$439.19
$516.98
52-Week Range
$331.75
$519.75
Volume
2.26 million shs
Average Volume
792,185 shs
Market Capitalization
$65.76 billion
P/E Ratio
19.53
Dividend Yield
0.50%
Price Target
$495.38

McKesson MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
2.6% Upside
$507.31 Price Target
Short Interest
Healthy
1.27% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.46mentions of McKesson in the last 14 days
Based on 44 Articles This Week
Insider Trading
Selling Shares
$6.73 M Sold Last Quarter
Proj. Earnings Growth
14.04%
From $27.27 to $31.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.73 out of 5 stars

Medical Sector

53rd out of 911 stocks

Drugs, Proprietaries, & Sundries Industry

3rd out of 6 stocks


MCK stock logo

About McKesson Stock (NYSE:MCK)

McKesson Corporation is a prominent player in the healthcare industry, offering a wide range of supply chain management solutions, retail pharmacy services, community oncology and specialty care, and healthcare information technology. With a rich history dating back to 1833, McKesson has established itself as a leading provider of essential healthcare products and services, contributing to the well-being of patients and the efficiency of healthcare providers.

The company's mission is to improve care in every setting, one product, partner, and patient at a time. McKesson operates globally, with a significant presence in the United States, Europe, and Canada, serving a diverse customer base, including hospitals, pharmacies, physician offices, surgery centers, nursing homes, and home health care agencies.

McKesson's operations are organized into several segments. The U.S. Pharmaceutical segment, one of the company's key pillars, is pivotal in distributing a comprehensive range of pharmaceutical drugs, including branded, generic, specialty, biosimilar, and over-the-counter medications. It is a crucial link in the pharmaceutical supply chain, ensuring the timely delivery of essential drugs to pharmacies and healthcare facilities across the United States.

In addition to pharmaceutical distribution, McKesson provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. The company empowers healthcare providers to optimize their practices, enhance patient care and improve overall efficiency by offering financial, operational, and clinical solutions.

McKesson's International segment extends its reach beyond the United States, providing distribution and services to wholesale, institutional, and retail customers in European countries and Canada. This global presence enables the company to leverage its expertise and resources to support healthcare systems and deliver high-quality products and services to a broader market.

The Medical-Surgical Solutions segment focuses on supply distribution, logistics, and other services. By catering to healthcare providers such as physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies, McKesson ensures that critical medical supplies are readily available, enabling efficient and effective patient care.

McKesson's management team is composed of highly experienced professionals who bring a wealth of expertise and strategic vision to the company. Led by Chief Executive Officer and Director Brian Scott Tyler, the team is dedicated to driving McKesson's mission forward. Brian Scott Tyler has been influential in steering the company toward continued growth and success. Under his leadership, McKesson has focused on innovation, strategic partnerships, and operational excellence. With a deep understanding of the healthcare landscape, Tyler has led the company through various challenges and has positioned it as a trusted partner for healthcare providers worldwide.

McKesson has consistently delivered strong financial performance, reflecting its ability to navigate the complexities of the healthcare industry while adapting to changing market dynamics. The company has demonstrated robust revenue growth over the years, driven by its diversified portfolio of products and services.

McKesson operates within the broader healthcare industry, characterized by continuous innovation, regulatory complexities, and a focus on patient care. As one of the largest healthcare distributors, McKesson faces competition from both traditional and emerging players in the market. However, the company's extensive distribution network, strong relationships with healthcare providers, and comprehensive product and service offerings give it a competitive edge.

The healthcare industry is subject to various regulatory and political factors impacting market dynamics. Changes in healthcare policies, reimbursement structures, and drug pricing regulations can significantly affect McKesson's operations. However, the company's deep industry knowledge and expertise enable it to navigate these challenges effectively.

McKesson is well-positioned to capitalize on several growth opportunities in the healthcare industry. One key area of focus is expanding its healthcare information technology solutions. As the digital transformation of the healthcare sector continues, McKesson's investments in technology and data analytics enable it to provide advanced solutions that enhance patient care, optimize workflows and drive operational efficiencies.

While McKesson has a strong market position and a track record of success, it faces certain risks and challenges that should be considered. One significant risk is the evolving regulatory landscape, including changes in healthcare policies and drug pricing regulations. Compliance with these regulations can increase costs and impact the company's profitability.

Additionally, competitive pressures within the healthcare industry require McKesson to continually innovate and differentiate its offerings. The emergence of new market entrants and disruptive technologies could challenge the company's market share and profitability.

The COVID-19 pandemic also introduced unprecedented challenges to the healthcare industry. While the pandemic presented opportunities for McKesson to support the healthcare system with essential supplies and services, it also disrupted healthcare operations and supply chains.

To mitigate these risks, McKesson has implemented robust risk management strategies. The company maintains strong relationships with regulatory bodies, stays abreast of industry trends, and invests in innovation and technology to stay ahead of the competition.

MCK Stock Price History

MCK Stock News Headlines

Multimillionaire Investor: "Hands Down the Most Lucrative Discovery of My Entire Career"
Peabody Award-winning journalist Bill Tucker sat down with a reclusive multimillionaire trader... 858 miles OUTSIDE of Wall Street... to discuss a revolutionary new trading strategy that involves...One ticker... one trade... every week.The fast-hitting profit potential is extraordinary.
Q3 2024 Mckesson Corp Earnings Call
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
McKesson: Fiscal Q3 Earnings Snapshot
McKesson Corp. Q3 Profit Decreases, but beats estimates
McKesson Q3 2024 Earnings Preview
Earnings Preview: McKesson
See More Headlines
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 1/2 Dividend
11/30/2023
Dividend Payable
1/02/2024
Last Earnings
2/07/2024
Today
2/08/2024
Ex-Dividend for 4/1 Dividend
2/29/2024
Fiscal Year End
3/31/2024
Dividend Payable
4/01/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
CUSIP
58155Q10
Employees
51,000
Year Founded
1833

Price Target and Rating

Average Stock Price Target
$495.38
High Stock Price Target
$563.00
Low Stock Price Target
$420.00
Potential Upside/Downside
+0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$3.56 billion
Pretax Margin
1.51%

Debt

Sales & Book Value

Annual Sales
$276.71 billion
Cash Flow
$31.24 per share
Book Value
($10.99) per share

Miscellaneous

Free Float
132,783,000
Market Cap
$65.38 billion
Optionable
Optionable
Beta
0.44

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Should I Buy McKesson Stock? MCK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of McKesson was last updated on Monday, January 29, 2024 at 1:44 PM.

Pros

Here are some ways that investors could benefit from investing in McKesson Co.:

  • Strong Institutional Ownership: McKesson Co. has a high percentage of institutional ownership, indicating confidence from large investors.
  • Positive Insider Activity: Recent insider selling by CEO Brian S. Tyler suggests that company executives have confidence in the company's future prospects.
  • Stable Dividend: McKesson Co. recently announced a quarterly dividend, providing a steady income stream for investors.
  • Positive Earnings Results: McKesson Co. reported better-than-expected earnings per share for the last quarter, indicating strong financial performance.
  • Market Leader in Healthcare Distribution: McKesson Co. is a leading provider of healthcare supply chain management solutions, giving it a competitive advantage in the industry.

Cons

Investors should be bearish about investing in McKesson Co. for these reasons:

  • Volatility in Stock Price: McKesson Co.'s stock price has experienced fluctuations, which may make it a riskier investment option.
  • Regulatory Challenges: The healthcare industry is subject to strict regulations, and any changes in regulations could impact McKesson Co.'s operations and profitability.
  • Competition in the Industry: McKesson Co. faces competition from other healthcare distributors, which could affect its market share and profitability.
  • Dependence on Healthcare Spending: McKesson Co.'s financial performance is closely tied to healthcare spending, and any slowdown in healthcare spending could impact its revenue.
  • Potential Legal Risks: As a large healthcare company, McKesson Co. may face legal risks and lawsuits, which could have financial implications.














MCK Stock Analysis - Frequently Asked Questions

Should I buy or sell McKesson stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MCK shares.
View MCK analyst ratings
or view top-rated stocks.

What is McKesson's stock price target for 2024?

10 brokers have issued 1 year target prices for McKesson's shares. Their MCK share price targets range from $450.00 to $575.00. On average, they anticipate the company's share price to reach $507.31 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price.
View analysts price targets for MCK
or view top-rated stocks among Wall Street analysts.

How have MCK shares performed in 2024?

McKesson's stock was trading at $462.98 at the beginning of 2024. Since then, MCK shares have increased by 6.7% and is now trading at $494.23.
View the best growth stocks for 2024 here
.

Are investors shorting McKesson?

McKesson saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,690,000 shares, an increase of 9.0% from the December 31st total of 1,550,000 shares. Based on an average daily volume of 816,400 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.3% of the company's stock are sold short.
View McKesson's Short Interest
.

When is McKesson's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our MCK earnings forecast
.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) announced its quarterly earnings results on Wednesday, February, 7th. The company reported $7.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.05 by $0.69. The business had revenue of $80.90 billion for the quarter, compared to analysts' expectations of $77.93 billion. McKesson had a negative trailing twelve-month return on equity of 241.79% and a net margin of 1.20%. The company's revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.90 earnings per share.
Read the conference call transcript
.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson declared a quarterly dividend on Thursday, February 1st. Stockholders of record on Friday, March 1st will be given a dividend of $0.62 per share on Monday, April 1st. This represents a $2.48 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 29th.
Read our dividend analysis for MCK
.

Is McKesson a good dividend stock?

McKesson (NYSE:MCK) pays an annual dividend of $2.48 per share and currently has a dividend yield of 0.49%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.80%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MCK will have a dividend payout ratio of 7.97% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MCK.

What guidance has McKesson issued on next quarter's earnings?

McKesson issued an update on its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided EPS guidance of 27.250-27.650 for the period, compared to the consensus estimate of 27.320. The company issued revenue guidance of $307.1 billion-$315.5 billion, compared to the consensus revenue estimate of $305.3 billion.

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson Chief Executive Officer Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among the company's employees.

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and Home Depot (HD).

Who are McKesson's major shareholders?

McKesson's stock is owned by a number of retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (3.78%), Boston Partners (0.85%), WCM Investment Management LLC (0.82%), International Assets Investment Management LLC (0.62%), LSV Asset Management (0.61%) and Charles Schwab Investment Management Inc. (0.60%). Insiders that own company stock include Brian S Tyler, Brian S Tyler, Britt J Vitalone, Kevin Emerson, Leann B Smith, Lori A Schechter, Lori A Schechter, Nancy Avila, Nancy Flores, Sundeep G Reddy, Thomas L Rodgers, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends
.

How do I buy shares of McKesson?

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does McKesson have any subsidiaries?
The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, LloydsDirect, MED3000, McKesson Europe AG, McKesson Europe Holdings GmbH & Co. KGaA, McKesson Global Procurement & Sourcing Limited, McKesson International Bermuda IP2A Limited, McKesson International Bermuda IP3A Limited, McKesson Ireland Limited, McKesson Medical-Surgical Holdings Inc., McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLP, McKesson Medical-Surgical Top Holdings Inc., McKesson Plasma and Biologics LLC, McKesson Specialty Care Distribution LLC, McKesson UK Finance I Limited, McKesson UK Finance II Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., US Oncology Inc., United Drug (Wholesale) Limited, United Drug Distributors Ireland Limited, Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.
Read More
This page (NYSE:MCK) was last updated on 2/8/2024 by MarketBeat.com Staff

My Account -